Acquired by Advanz Pharma in Nov 2023
ICPT - Intercept Pharmaceuticals, Inc.
NASDAQ
->
Healthcare
->
Biotechnology
New York,
United States
Type: Equity
ICPT price evolution
ICPT
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Jan 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $103.66 | $137.36 | $63.02 | $55.86 |
| Short term investments | $219.98 | $277.63 | $372.19 | $435.05 |
| Net receivables | $32.48 | $29.79 | $28.75 | $26.86 |
| Inventory | $2.65 | $6.27 | $6.46 | $6.46 |
| Total current assets | $383.44 | $470.77 | $490.46 | $540.13 |
| Long term investments | ||||
| Property, plant & equipment | $0.82 | $0.91 | $0.9 | $6.11 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $9.72 | $13.87 | $13.63 | $13.58 |
| Total investments | $219.98 | $277.63 | $372.19 | $435.05 |
| Total assets | $393.16 | $484.63 | $504.08 | $553.71 |
| Current liabilities | ||||
| Accounts payable | $89.49 | $73.68 | $95.19 | $14.23 |
| Deferred revenue | ||||
| Short long term debt | $109.81 | $109.69 | $109.57 | |
| Total current liabilities | $90.84 | $187.02 | $207.12 | $230.08 |
| Long term debt | $223.86 | $223.6 | $223.35 | $223.1 |
| Total noncurrent liabilities | $230.47 | $230.07 | $229.78 | $230.56 |
| Total debt | $223.86 | $333.41 | $333.04 | $332.67 |
| Total liabilities | $321.32 | $417.09 | $436.9 | $460.63 |
| Shareholders' equity | ||||
| Retained earnings | -$2177.68 | -$2174.89 | -$2169.02 | -$2136.89 |
| Other shareholder equity | -$7.2 | -$7.62 | -$7.62 | -$8.26 |
| Total shareholder equity | $71.84 | $67.55 | $67.19 | $93.08 |
| (in millions $) | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $55.86 | $94.41 | $65.65 | $74.78 |
| Short term investments | $435.05 | $334.98 | $411.52 | $582.57 |
| Net receivables | $26.86 | $47.62 | $41.55 | $38.04 |
| Inventory | $6.46 | $8.62 | $9.03 | $8.46 |
| Total current assets | $540.13 | $502.29 | $545.74 | $721.32 |
| Long term investments | ||||
| Property, plant & equipment | $6.11 | $3.38 | $6.33 | $5.2 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | $13.58 | $24.73 | $34.75 | $33.57 |
| Total investments | $435.05 | $334.98 | $411.52 | $582.57 |
| Total assets | $553.71 | $527.02 | $580.49 | $754.89 |
| Current liabilities | ||||
| Accounts payable | $14.23 | $158.22 | $171.04 | $153.97 |
| Deferred revenue | ||||
| Short long term debt | $109.57 | |||
| Total current liabilities | $230.08 | $166.82 | $179.08 | $162 |
| Long term debt | $223.1 | $539.78 | $560.58 | $532.08 |
| Total noncurrent liabilities | $230.56 | $544.17 | $568.27 | $541.33 |
| Total debt | $332.67 | $539.78 | $560.58 | $532.08 |
| Total liabilities | $460.63 | $710.99 | $747.34 | $703.33 |
| Shareholders' equity | ||||
| Retained earnings | -$2136.89 | -$2489.77 | -$2398.35 | -$2123.47 |
| Other shareholder equity | -$8.26 | -$2.87 | -$2.48 | -$1.14 |
| Total shareholder equity | $93.08 | -$183.96 | -$166.85 | $51.56 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $88.79 | $83.72 | $67.96 | $77.22 |
| Cost of revenue | $0.2 | $0.18 | $0.22 | $0.03 |
| Gross Profit | $88.59 | $83.53 | $67.74 | $77.19 |
| Operating activities | ||||
| Research & development | $41.51 | $37.31 | $41.71 | $39.89 |
| Selling, general & administrative | $45.44 | $53.35 | $57.66 | $55.29 |
| Total operating expenses | $93.21 | $90.65 | $99.37 | $95.18 |
| Operating income | -$4.62 | -$7.12 | -$31.63 | -$17.98 |
| Income from continuing operations | ||||
| EBIT | -$0.99 | -$3.05 | -$29.33 | -$18.02 |
| Income tax expense | ||||
| Interest expense | $1.8 | $2.81 | $2.81 | $2.81 |
| Net income | ||||
| Net income | -$2.79 | -$5.86 | -$32.13 | -$20.82 |
| Income (for common shares) | -$2.79 | -$5.86 | -$32.13 | -$20.82 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $285.71 | $363.47 | $312.69 | $252 |
| Cost of revenue | $0.98 | $3.1 | $5.32 | $4.21 |
| Gross Profit | $284.73 | $360.37 | $307.37 | $247.79 |
| Operating activities | ||||
| Research & development | $176.64 | $185.27 | $191.49 | $242.8 |
| Selling, general & administrative | $176.3 | $230.85 | $332.49 | $317.42 |
| Total operating expenses | $352.94 | $416.04 | $538.61 | $560.22 |
| Operating income | -$68.22 | -$55.67 | -$231.24 | -$312.43 |
| Income from continuing operations | ||||
| EBIT | $243.2 | -$37.01 | -$226.83 | -$303.54 |
| Income tax expense | ||||
| Interest expense | $21.39 | $54.42 | $48.05 | $41.14 |
| Net income | ||||
| Net income | $221.82 | -$91.43 | -$274.88 | -$344.68 |
| Income (for common shares) | $221.82 | -$91.43 | -$274.88 | -$344.68 |
| (in millions $) | 30 Sep 2023 | 30 Jun 2023 | 31 Mar 2023 | 31 Dec 2022 |
|---|---|---|---|---|
| Net income | -$2.79 | -$5.86 | -$32.13 | -$20.82 |
| Operating activities | ||||
| Depreciation | -$0.51 | $0.44 | $0.35 | $0.33 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $6.65 | $6.26 | $5.86 | $5.23 |
| Total cash flows from operations | $16.69 | -$23.3 | -$51.6 | -$4.81 |
| Investing activities | ||||
| Capital expenditures | -$0.01 | -$0.1 | $0.3 | |
| Investments | $59.79 | $96.97 | $65.55 | -$55.23 |
| Total cash flows from investing | $59.77 | $96.95 | $59.32 | -$54.94 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $0.05 | $0.01 | $0.01 | $1.25 |
| Net borrowings | -$110.02 | -$6.85 | ||
| Total cash flows from financing | -$110 | -$0.04 | -$0.25 | -$5.67 |
| Effect of exchange rate | -$0.17 | $0.74 | -$0.31 | $1.1 |
| Change in cash and equivalents | -$33.7 | $74.34 | $7.16 | -$64.32 |
| (in millions $) | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 | 31 Dec 2019 |
|---|---|---|---|---|
| Net income | $221.82 | -$91.43 | -$274.88 | -$344.68 |
| Operating activities | ||||
| Depreciation | $2.26 | $8.76 | $9.26 | $9.05 |
| Business acquisitions & disposals | ||||
| Stock-based compensation | $21.89 | $33.89 | $60.85 | $55.98 |
| Total cash flows from operations | -$26.78 | -$41.64 | -$170.03 | -$236.61 |
| Investing activities | ||||
| Capital expenditures | -$0.57 | -$0.4 | -$3.89 | -$1.14 |
| Investments | -$100.82 | $71.12 | $166.71 | -$187.85 |
| Total cash flows from investing | $261.85 | $70.73 | $162.82 | -$188.99 |
| Financing activities | ||||
| Dividends paid | ||||
| Sale and purchase of stock | $1.68 | -$75.81 | $1.3 | $236.25 |
| Net borrowings | -$268.44 | -$38.13 | $223.42 | |
| Total cash flows from financing | -$267.32 | $1.12 | -$0.69 | $457.52 |
| Effect of exchange rate | -$6.3 | -$1.45 | -$1.22 | -$0.39 |
| Change in cash and equivalents | -$38.55 | $28.75 | -$9.13 | $31.53 |
News
Fundamentals
| Market cap | N/A |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 41.81M |
| Revenue | $317.68M |
|---|---|
| EBITDA | -$50.77M |
| EBIT | -$51.38M |
| Net Income | -$61.61M |
| Revenue Q/Q | 14.44% |
| Revenue Y/Y | -3.83% |
| P/E ratio | 0.00 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 0.00 |
| Book/Share | 1.89 |
| Cash/Share | 2.48 |
| EPS | -$1.47 |
|---|---|
| ROA | -12.73% |
| ROE | -82.24% |
| Debt/Equity | 4.95 |
|---|---|
| Net debt/EBITDA | -4.29 |
| Current ratio | 4.22 |
| Quick ratio | 4.19 |